Our results also demonstrate that MAFG might be the primary target that mediates the effect of hepatic miR-378 on BA and cholesterol metabolism, while miR-378 and MAFG could serve as therapeutic targets for the treatment of hypercholesterolemia. The gene discussed is MAFG; the disease is Hypercholesterolemia.